Access
To read this story in full you will need to login or make a payment (see right).
Article
Nature 451, 141-146 (10 January 2008) | doi:10.1038/nature06534; Received 16 November 2007; Accepted 10 December 2007; Published online 23 December 2007
nature jobs
Postdoctoral Fellow in Immunology
- The Scripps Research Institute
- N Torrey Pines Rd, San Diego, CA, USA
Executive- Commercial- Corporate Office
- Rhydburg Pharmaceuticals
- Selaqui-Dehradun India
Reprogramming of human somatic cells to pluripotency with defined factors
In-Hyun Park1, Rui Zhao1, Jason A. West1, Akiko Yabuuchi1, Hongguang Huo1, Tan A. Ince2, Paul H. Lerou3, M. William Lensch1 & George Q. Daley1
- Division of Pediatric Hematology/Oncology, Children's Hospital Boston and Dana Farber Cancer Institute; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School; Division of Hematology, Brigham & Women's Hospital, Boston, Massachusetts 02115, USA; and Harvard Stem Cell Institute, Cambridge, Massachusetts 02138, USA
- Department of Pathology, Brigham and Women's Hospital, and,
- Division of Newborn Medicine, Brigham & Women's Hospital and Children's Hospital Boston, Boston, Massachusetts 02115, USA
Correspondence to: George Q. Daley1 Correspondence and requests for materials should be addressed to G.Q.D. (Email: george.daley@childrens.harvard.edu).
Abstract
Pluripotency pertains to the cells of early embryos that can generate all of the tissues in the organism. Embryonic stem cells are embryo-derived cell lines that retain pluripotency and represent invaluable tools for research into the mechanisms of tissue formation. Recently, murine fibroblasts have been reprogrammed directly to pluripotency by ectopic expression of four transcription factors (Oct4, Sox2, Klf4 and Myc) to yield induced pluripotent stem (iPS) cells. Using these same factors, we have derived iPS cells from fetal, neonatal and adult human primary cells, including dermal fibroblasts isolated from a skin biopsy of a healthy research subject. Human iPS cells resemble embryonic stem cells in morphology and gene expression and in the capacity to form teratomas in immune-deficient mice. These data demonstrate that defined factors can reprogramme human cells to pluripotency, and establish a method whereby patient-specific cells might be established in culture.
- Division of Pediatric Hematology/Oncology, Children's Hospital Boston and Dana Farber Cancer Institute; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School; Division of Hematology, Brigham & Women's Hospital, Boston, Massachusetts 02115, USA; and Harvard Stem Cell Institute, Cambridge, Massachusetts 02138, USA
- Department of Pathology, Brigham and Women's Hospital, and,
- Division of Newborn Medicine, Brigham & Women's Hospital and Children's Hospital Boston, Boston, Massachusetts 02115, USA
Correspondence to: George Q. Daley1 Correspondence and requests for materials should be addressed to G.Q.D. (Email: george.daley@childrens.harvard.edu).
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Debugging cellular reprogrammingNature Cell Biology News and Views (01 Aug 2007)
Stem cells Tips for priming potencyNature News and Views (03 Jul 2008)
See all 8 matches for News And ViewsRESEARCH
In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like stateNature Article (19 Jul 2007)
Linking the p53 tumour suppressor pathway to somatic cell reprogrammingNature Letters to Editor (27 Aug 2009)
See all 47 matches for Research
